Cantitate/Preț
Produs

Renal Pharmacotherapy: Dosage Adjustment of Medications Eliminated by the Kidneys

Autor Larry K. Golightly, Isaac Teitelbaum, Bonita A. Simendinger, Tyree H. Kiser, Gerard R. Barber, Nancy M. Stolpman
en Limba Engleză Paperback – 25 sep 2021

To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function.  Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications.

This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys.  Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types.

Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.



Citește tot Restrânge

Preț: 60149 lei

Preț vechi: 63315 lei
-5% Nou

Puncte Express: 902

Preț estimativ în valută:
11515 11969$ 9547£

Carte tipărită la comandă

Livrare economică 03-08 februarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783030586492
ISBN-10: 3030586499
Pagini: 827
Ilustrații: XXVI, 827 p. 2 illus.
Dimensiuni: 210 x 279 mm
Greutate: 2.27 kg
Ediția:2nd ed. 2021
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland

Cuprins

A: Acamprosate to Aztreonam
B: Bacitracin to Butorphanol
C: Capecitabine to Cycloserine
D: Dabigatran to Dyphylline
E: Edetate Calcium Disodium to Exenatide
F: Famciclovir to Fosfomycin
G: Gabapentin to Glyburide
H: Hetastarch to Hydroxyurea
I: Ibandronate to Itraconazole
K: Kanamycin to Ketorolac
L: Lacosamide to Lurasidone
M: Magnesium Citrate to Mycophenolate Mofetil
N: Nabumetone to Norfloxacin
O: Ofloxacin to Oxcarbazepine
P: Paliperidone to Pyridostigmine
Q: Quinapril to Quinine
R: Ramipril to Ruxolitinib
S: Salsalate to Sunitinib
T: Tadalafil to Trospium
V: Valacyclovir to Voriconazole
Z: Zalcitabine to Zonisamide
Proprietary Name Index


Notă biografică

Larry K. Golightly, PharmD
Clinical Research Pharmacist
University of Colorado Hospital
Aurora, CO 80045 larry.golightly@uchealth.org
 
Isaac Teitelbaum, MD, FACP Professor of Medicine
Renal Medicine and Hypertension Section, Division of General Internal Medicine
University of Colorado School of Medicine and
Director, Home Dialysis Program
University of Colorado Hospital
Aurora, CO 80045
isaac.teitelbaum@cuanschutz.edu
 
Bonita A. Simendinger, PharmD, BCPS
P&T Formulary Compliance Specialist
University of Colorado Hospital
Aurora, CO 80045
bonita.simendinger@uchealth.org
 
Tyree H. Kiser, PharmD, BCPS, FCCP, FCCM
Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and Critical Care Pharmacy Specialist
University of Colorado Hospital
Aurora, CO 80045
ty.kiser@cuanschutz.edu
 
Gerard R. Barber, RPh, MPH, FASHP
Clinical Assistant Professor, Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, CO 80045
gerard.barber@cuanschutz.edu
 
Nancy M. Stolpman, PharmD, PhD
Associate Clinical Professor
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and
Lead Director of Pharmacy
UCHealth
Aurora, CO 80045
nancy.stolpman@uchealth.org


Textul de pe ultima copertă

 


To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function.  Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications.


This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys.  Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types.


Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.



 

 


Caracteristici

Renal Pharmacotherapy is a comprehensive and evidence-based listing of dosage recommendations for patients with compromised renal function
This updated edition closes several identified knowledge gaps concerning medications eliminated by the kidneys
Nephrologists and a broad range of health professionals will be interested in this reference

Descriere

 
To promote effectiveness and minimize possible toxicity, the dosage of certain medications must be adjusted in persons with compromised kidney function.  Failure to enjoin appropriate dosage adjustments in patients with abnormal or rapidly changing kidney function continues to lead to reports of drug toxicity involving a broad array of renally eliminated medications.
 
This updated edition captures nearly 200 new drugs that have been approved by the FDA since the initial publication of Renal Pharmacotherapy. It also covers new evidence that has emerged regarding the need to adjust dosage of certain older medications that are eliminated by the kidneys.  Additionally, it presents new data that are being continuously derived in the areas of patient-specific dose individualization for drugs of all types.
 
Comprehensive, convenient, and evidence-based, this reference closes several identified knowledge gaps and will continue to be the leading collection of dosage recommendations for patients with compromised kidney function.